Home LiteratureArticle Details
PMID: 27780254 Published · epublish English Journal Article Meta-Analysis

The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-Analysis.

PloS one ·Vol. 11 ·No. 10 ·2016-00-00 ·Pages e0164514

Zhang S, Ma X, Zhu C, Liu L, Wang G, Yuan X

Abstract

Targeting immune cells or factors are effective for patients with solid tumors. Myeloid-derived suppressor cells (MDSCs) are known to have immunosuppressive functions, and the levels of MDSCs in patients with solid tumor are assumed to have prognostic values. This meta-analysis aimed at evaluating the relationship between MDSCs and the prognosis of patients with solid tumors. We searched articles in PUBMED and EMBASE comprehensively, updated to March 2016. Eight studies with 442 patients were included in the meta-analysis. We analyzed pooled hazard ratios (HRs) for overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS). The results showed that MDSCs were associated with poor OS (HR, 1.94; 95% confidence interval [CI], 1.42-2.66; P < 0.0001) in patients with solid tumors. PFS/RFS (HR, 1.85; 95% CI, 1.16-2.97; P = 0.01) also indicated the association between MDSCs and prognosis. The HRs and 95% CIs for OS in Asian and non-Asian patients were 2.53 (95% CI 1.61-3.42, p < 0.00001) and 1.67 (95% CI 1.14-2.46, p < 0.0001), respectively. We further analyzed the data according to tumor types. The combined HRs and 95% CIs for OS were 1.26 (95% CI 1.10-1.44, p = 0.0003) for gastrointestinal (GI) cancer, 2.59 (95% CI 1.69-3.98, p < 0.0001) for hepatocellular carcinoma (HCC) and 1.86 (95% CI 1.26-2.75, p = 0.002) for other tumor types. In conclusion, MDSCs had a fine prognostic value for OS and PFS/RFS in patients with solid tumors. MDSCs could be used as biomarkers to evaluate prognosis in clinical practice.

MeSH Terms
Disease-Free Survival Humans Myeloid-Derived Suppressor Cells/pathology Neoplasms/pathology Prognosis Proportional Hazards Models
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Zhang Shuo
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, PR China.
Ma Xuelei
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, PR China.
Zhu Chenjing
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, PR China.
Liu Li
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, PR China.
Wang Guoping
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, PR China.
Yuan Xia
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, PR China.
Conflict of Interest

The authors have declared that no competing interests exist.

References (37)
37 references, click to expand
  1. A mouse model for breast cancer induced by amplification and overexpression of the neu promoter and transgene.
    Mol Med. 2000 Jan;6(1):4-16 PMID: 10803404
  2. Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries.
    Lancet. 2001 Sep 15;358(9285):870-5 PMID: 11567701
  3. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis.
    J Clin Epidemiol. 2001 Oct;54(10):1046-55 PMID: 11576817
  4. Measuring inconsistency in meta-analyses.
    BMJ. 2003 Sep 6;327(7414):557-60 PMID: 12958120
  5. Cancer of the gastrointestinal tract: early detection or early prevention?
    Eur J Cancer Prev. 2004 Feb;13(1):71-5 PMID: 15075791
  6. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis.
    Cancer Cell. 2004 Oct;6(4):409-21 PMID: 15488763
  7. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
    N Engl J Med. 2005 Oct 20;353(16):1673-84 PMID: 16236738
  8. Selective COX-2 inhibitor, NS-398, suppresses cellular proliferation in human hepatocellular carcinoma cell lines via cell cycle arrest.
    World J Gastroenterol. 2007 Feb 28;13(8):1175-81 PMID: 17451196
  9. Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis.
    Breast Cancer Res Treat. 2009 Apr;114(3):423-31 PMID: 18425677
  10. The role of myeloid cells in the promotion of tumour angiogenesis.
    Nat Rev Cancer. 2008 Aug;8(8):618-31 PMID: 18633355
  11. Myeloid-derived suppressor cells: linking inflammation and cancer.
    J Immunol. 2009 Apr 15;182(8):4499-506 PMID: 19342621
  12. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
    BMJ. 2009 Jul 21;339:b2535 PMID: 19622551
  13. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity.
    Cancer Immunol Immunother. 2010 Oct;59(10):1593-600 PMID: 20414655
  14. Myeloid derived suppressor cells and their role in tolerance induction in cancer.
    J Dermatol Sci. 2010 Jul;59(1):1-6 PMID: 20570112
  15. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.
    Eur J Epidemiol. 2010 Sep;25(9):603-5 PMID: 20652370
  16. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity.
    Eur J Immunol. 2010 Nov;40(11):2969-75 PMID: 21061430
  17. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.
    Cancer Immunol Immunother. 2011 Sep;60(9):1269-79 PMID: 21604071
  18. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.
    Cancer Immunol Immunother. 2011 Oct;60(10):1419-30 PMID: 21644036
  19. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.
    Blood. 2011 Aug 25;118(8):2254-65 PMID: 21734236
  20. The immune score as a new possible approach for the classification of cancer.
    J Transl Med. 2012 Jan 03;10:1 PMID: 22214470
  21. Coordinated regulation of myeloid cells by tumours.
    Nat Rev Immunol. 2012 Mar 22;12(4):253-68 PMID: 22437938
  22. Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma.
    World J Gastroenterol. 2012 Jul 7;18(25):3303-9 PMID: 22783056
  23. Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies.
    Cancer Immunol Immunother. 2013 Feb;62(2):299-307 PMID: 23011590
  24. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.
    Immunology. 2013 Feb;138(2):105-15 PMID: 23216602
  25. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature.
    PLoS One. 2012;7(12):e50946 PMID: 23284651
  26. Increased circulating Lin(-/low) CD33(+) HLA-DR(-) myeloid-derived suppressor cells in hepatocellular carcinoma patients.
    Hepatol Res. 2014 Jun;44(6):639-50 PMID: 23701406
  27. Myeloid derived suppressor cells: Targets for therapy.
    Oncoimmunology. 2013 Apr 1;2(4):e24117 PMID: 23734336
  28. Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.
    Cancer Immunol Immunother. 2013 Aug;62(8):1421-30 PMID: 23764929
  29. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.
    J Pathol. 2014 Jan;232(2):199-209 PMID: 24122236
  30. Myeloid-derived suppressor cells in glioma.
    Expert Rev Neurother. 2013 Dec;13(12):1395-406 PMID: 24215283
  31. Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.
    Cancer J. 2013 Nov-Dec;19(6):490-501 PMID: 24270348
  32. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
    Int J Cancer. 2015 Mar 1;136(5):E359-86 PMID: 25220842
  33. Editorial: The intricacy of choice: can bacteria decide what type of myeloid cells to stimulate?
    J Leukoc Biol. 2014 Nov;96(5):671-4 PMID: 25360040
  34. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.
    Br J Haematol. 2015 Mar;168(5):689-700 PMID: 25376846
  35. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.
    Syst Rev. 2015 Jan 01;4:1 PMID: 25554246
  36. The clinical and prognostic significance of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy.
    Tumour Biol. 2016 Aug;37(8):10427-33 PMID: 26846107
  37. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.
    Stat Med. 1998 Dec 30;17(24):2815-34 PMID: 9921604
Article Info
Journal
PloS one
Abbr.
PLoS One
ISSN
1932-6203
DOI
10.1371/journal.pone.0164514
Published
2016-00-00
Epub
2016-00-25
Pages
e0164514
Language
English
Region
United States
NLM ID
101285081
PMCID
PMC5079654
Subset
IM
External Links
PubMed source DOI: 10.1371/journal.pone.0164514 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2